GeneseeqPrime
FDA-cleared next-generation sequencing tumor-profiling assay for FFPE solid-tumor tissue.
- Developer
- Geneseeq
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA mutation
- Current version
- GENESEEQPRIME NGS Tumor Profiling Assay (FFPE), K250003
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.